BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29567781)

  • 1. A novel regimen for relapsed/refractory adult acute myeloid leukemia using a
    Mims AS; Mishra A; Orwick S; Blachly J; Klisovic RB; Garzon R; Walker AR; Devine SM; Walsh KJ; Vasu S; Whitman S; Marcucci G; Jones D; Heerema NA; Lozanski G; Caligiuri MA; Bloomfield CD; Byrd JC; Piekarz R; Grever MR; Blum W
    Haematologica; 2018 Jun; 103(6):982-987. PubMed ID: 29567781
    [No Abstract]   [Full Text] [Related]  

  • 2. The Application of Targeted RNA Sequencing for KMT2A-Partial Tandem Duplication Identification and Integrated Analysis of Molecular Characterization in Acute Myeloid Leukemia.
    Dai B; Yu H; Ma T; Lei Y; Wang J; Zhang Y; Lu J; Yan H; Jiang L; Chen B
    J Mol Diagn; 2021 Nov; 23(11):1478-1490. PubMed ID: 34384895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
    Vetro C; Haferlach T; Meggendorfer M; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2020 Jan; 240():15-22. PubMed ID: 31698332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
    Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
    Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
    Szotkowski T; Jarošová M; Zimmermannová O; Meyer C; Marschalek R; Zuna J; Hubáček J; Indrák K
    Cancer Genet; 2015 Dec; 208(12):610-4. PubMed ID: 26556690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia.
    Kong J; Zhao XS; Qin YZ; Zhu HH; Jia JS; Jiang Q; Wang J; Zhao T; Huang XJ; Jiang H
    Leuk Lymphoma; 2018 Apr; 59(4):967-972. PubMed ID: 28745571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
    Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
    Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital acute myeloid leukaemia with KMT2A rearrangement.
    Wan Ariffin E; Jones H; Bhatnagar N
    Br J Haematol; 2018 Jul; 182(2):169. PubMed ID: 29797490
    [No Abstract]   [Full Text] [Related]  

  • 10. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
    Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
    Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
    Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
    Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival.
    Tong J; Zhang L; Liu H; Xu X; Zheng C; Yao W; Zhu X; Tang B; Wan X; Song K; Zhang X; Sun G; Sun Z
    Ann Hematol; 2021 May; 100(5):1303-1309. PubMed ID: 33469688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
    Gojo I; Tan M; Fang HB; Sadowska M; Lapidus R; Baer MR; Carrier F; Beumer JH; Anyang BN; Srivastava RK; Espinoza-Delgado I; Ross DD
    Clin Cancer Res; 2013 Apr; 19(7):1838-51. PubMed ID: 23403629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes.
    Tsai HK; Gibson CJ; Murdock HM; Davineni P; Harris MH; Wang ES; Gondek LP; Kim AS; Nardi V; Lindsley RC
    Blood Adv; 2022 Jul; 6(14):4236-4240. PubMed ID: 35584376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial tandem duplication of
    Choi SM; Dewar R; Burke PW; Shao L
    Haematologica; 2018 Mar; 103(3):e131-e134. PubMed ID: 29351983
    [No Abstract]   [Full Text] [Related]  

  • 17. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
    Schnittger S; Kinkelin U; Schoch C; Heinecke A; Haase D; Haferlach T; Büchner T; Wörmann B; Hiddemann W; Griesinger F
    Leukemia; 2000 May; 14(5):796-804. PubMed ID: 10803509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
    Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
    Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
    Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y
    Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.